SEOM clinical guidelines in advanced and recurrent breast cancer (2018)-Reference-Cited by-同舟云学术

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

Published:2019-01 Issue:1 Volume:21 Page:31-45
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Chacón López-Muñiz J. I.^ORCID,de la Cruz Merino L.,Gavilá Gregori J.,Martínez Dueñas E.,Oliveira M.,Seguí Palmer M. A.,Álvarez López I.,Antolin Novoa S.,Bellet Ezquerra M.,López-Tarruella Cobo S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s12094-018-02010-w/fulltext.html

Reference111 articles.

1. Las cifras del cáncer en España. 2018. https://www.seom.org/es/noticias/106525-las-cifras-del-cancer-en-espana-2018 (internet; cited 2018 Aug 15).

2. Malmgren JA, Mayer M, Atwood MK, Kaplan HG. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat. 2018;167:579–90.

3. (2018). Lib_El_AlamoIII_Anexo_I.pdf. https://www.geicam.org/wp-content/uploads/2017/04/Lib_El_AlamoIII_Anexo_I.pdf (internet; cited 2018 Aug 15).

4. Grade definitions—US Preventive Services Task Force. 2018. https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions (internet; cited 2018 Nov 7).

5. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy192/5055519 (internet; cited 2018 Aug 15).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective study of do-not-do practice recommendations in metastatic breast cancer in Spain;Revista de Senología y Patología Mamaria;2024-07

2. Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool;Clinical and Translational Oncology;2023-06-27

3. Futuro y líneas de investigación clínica del cáncer de mama luminal metastásico;Revisiones en Cáncer;2023

4. Primera línea de tratamiento sistémico del cáncer de mama metastásico triple negativo;Revisiones en Cáncer;2023

5. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial;The Breast;2022-12